Paid Clinical Trials Milwaukee
Discover 757 paid clinical trials in Milwaukee, Wisconsin. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Sponsor:
Cytokinetics
Location:
Code:
NCT06412666
Conditions
Pediatric
Symptomatic Obstructive Hypertrophic Cardiomyopathy
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Aficamten
Placebo
Multi-session, Personalized Cognitive Bias Modification for Thought-Action-FusionMulti-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion
Sponsor:
Han Joo Lee
Location:
Code:
NCT06731426
Conditions
OCD
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CBM-TAF
CBM-SMP
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaStudy to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Sponsor:
C4 Therapeutics, Inc.
Location:
Code:
NCT04756726
Conditions
Multiple Myeloma
Lymphoma, Non-Hodgkin's
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
cemsidomide
Dexamethasone Oral
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentKRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Sponsor:
Kartos Therapeutics, Inc.
Location:
Code:
NCT03662126
Conditions
Primary Myelofibrosis (PMF)
Post-Polycythemia Vera MF (Post-PV-MF)
Post-Essential Thrombocythemia MF (Post-ET-MF)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
KRT-232
Best Available Therapy (BAT)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Sponsor:
GB002, Inc.
Location:
Code:
NCT05934526
Conditions
Pulmonary Arterial Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo
Seralutinib
Generic Dry Powder Inhaler
CUped: An Approach to Motor Recovery Post-Stroke, Not CompensationCUped: An Approach to Motor Recovery Post-Stroke, Not Compensation
Sponsor:
Marquette University
Location:
Code:
NCT06329765
Conditions
Stroke
Hemiplegia
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.
VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart DiseaseVictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
Sponsor:
Duke University
Location:
Code:
NCT06249165
Conditions
Atherosclerotic Cardiovascular Disease
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Inclisiran
A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaA Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
Sponsor:
AstraZeneca
Location:
Code:
NCT06502366
Conditions
Asthma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BDA MDI HFO 160/180 μg
BDA MDI HFA 160/180 μg
Placebo MDI HFA